Reliability of tumor-infiltrating lymphocyte and tertiary lymphoid structure assessment in human breast cancer.

Auteurs : Buisseret L, Desmedt C, Garaud S, Fornili M, Wang X, Van den Eyden G, de Wind A, Duquenne S, Boisson A, Naveaux C, Rothé F, Rorive S, Decaestecker C, Larsimont D, Piccart-Gebhart M, Biganzoli E, Sotiriou C, Willard-Gallo K
Année : 2017
Journal : Mod Pathol
Volume : 30(9)
Pages : 1204-1212

Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations.

Auteurs : Brown D, Smeets D, Székely B, Larsimont D, Szász AM, Adnet PY, Rothé F, Rouas G, Nagy ZI, Faragó Z, Dank M, Szentmártoni G, Udvarhelyi N, Zoppoli G, Pusztai L, Piccart-Gebhart M, Kulka J, Lambrechts D, Sotiriou C, Desmedt C
Année : 2017
Journal : Nat Commun
Volume : 8
Pages : 14944

Transcriptomic and genomic features of invasive lobular breast cancer.

Auteurs : Desmedt C, Zoppoli G, Sotiriou C, Salgado R
Année : 2017
Journal : Semin Cancer Biol
Volume : 44
Pages : 98-105

Somatic mutations reveal asymmetric cellular dynamics in the early human embryo.

Auteurs : Ju YS, Martincorena I, Gerstung M, Petljak M, Alexandrov LB, Rahbari R, Wedge DC, Davies HR, Ramakrishna M, Fullam A, Martin S, Alder C, Patel N, Gamble S, OMeara S, Giri DD, Sauer T, Pinder SE, Purdie CA, Borg Å, Stunnenberg H, van de Vijver M, Tan BK, Caldas C, Tutt A, Ueno NT, van t Veer LJ, Martens JW, Sotiriou C, Knappskog S, Span PN, Lakhani SR, Eyfjörd JE, Børresen-Dale AL, Richardson A, Thompson AM, Viari A, Hurles ME, Nik-Zainal S, Campbell PJ, Stratton MR
Année : 2017
Journal : Nature
Volume : 543
Pages : 714-718

HER2-overexpressing breast cancers amplify FGFR signaling upon acquisition of resistance to dual therapeutic blockade of HER2.

Auteurs : Hanker AB, Garrett JG, Estrada MV, Moore PD, Ericsson PG, Koch JP, Langley E, Singh S, Kim PS, Frampton GM, Sanford EM, Owns P, Becker J, Groseclose MR, Castellino S, Joensuu H, Huober J, Brase JC, Samira M, Brohée S, Venet D, Brown D, Baselga J, Piccart-Gebhart M, Sotiriou C, Arteaga CL
Année : 2017
Journal : Clin Cancer Res
Volume : 23(15)
Pages : 4323-4334

HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.

Auteurs : Davies H, Glodzik D, Morganella S, Yates LR, Staaf J, Zou X, Ramakrishna M, Martin S, Boyault S, Sieuwerts AM, Simpson PT, King TA, Raine K, Eyfjord JE, Kong G, Borg Å, Birney E, Stunnenberg HG, Van de Vijver MJ, Børresen-Dale AL, Martens JW, Span PN, Lakhani SR, Vincent-Salomon A, Sotiriou C, Tutt A, Thompson AM, Van Laere S, Richardson AL, Viari A, Campbell PJ, Stratton MR, Nik-Zainal S
Année : 2017
Journal : Nat Med
Volume : 23(4)
Pages : 517-525

Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.

Auteurs : Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Peña L, Loi S, Rosa DD, Chia S, Wardley A, Ueno T, Rossari J, Eidtmann H, Armour A, Piccart-Gebhart M, Rimm DL, Baselga J, Pusztai L
Année : 2017
Journal : Ann Oncol
Volume : 28
Pages : 128-135

The prognostic role of androgen receptor in patients with early stage breast cancer: A meta-analysis of clinical and gene expression data.

Auteurs : Bozovic-Spasojevic I, Zardavas D, Brohée S, Ameye L, Fumagalli D, Ades F, de Azambuja E, Bareche Y, Piccart-Gebhart M, Paesmans M, Sotiriou C
Année : 2017
Journal : Clin Cancer Res
Volume : 23(11)
Pages : 2702-2712

The AURORA pilot study for molecular screening of patients with advanced breast cancer-a study of the breast international group.

Auteurs : Maetens M, Brown D, Irrthum A, Aftimos P, Viale G, Loibl S, Laes JF, Campbell PJ, Thompson A, Cortes J, Seiler S, Vinnicombe S, Oliveira M, Rothé F, Bareche Y, Fumagalli D, Zardavas D, Desmedt C, Piccart-Gebhart M, Loi S, Sotiriou C
Année : 2017
Journal : NPJ Breast Cancer
Volume : 3
Pages : 23

The footprint of the ageing stroma in older patients with breast cancer.

Auteurs : Brouwers B, Fumagalli D, Brohee S, Hatse S, Govaere O, Floris G, Van den Eynde K, Bareche Y, Schöffski P, Smeets A, Neven P, Lambrechts D, Sotiriou C, Wildiers H
Année : 2017
Journal : Breast Cancer Res
Volume : 19
Pages : 78

DNA methylation-based immune response signature improves patient diagnosis in multiple cancers.

Auteurs : Jeschke J, Bizet M, Desmedt C, Calonne E, Dedeurwaerder S, Garaud S, Koch A, Larsimont D, Salgado R, Van den Eynden G, Willard-Gallo K, Bontempi G, Defrance M, Sotiriou C, Fuks F
Année : 2017
Journal : J Clin Invest
Volume : 127(8)
Pages : 3090-3102

CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib.

Auteurs : Raspé E, Coulonval K, Pita JM, Paternot S, Rothé F, Twyffels L, Brohée S, Craciun L, Larsimont D, Kruys V, Sandras F, Salmon I, Van Laere S, Piccart-Gebhart M, Ignatiadis M, Sotiriou C, Roger PP
Année : 2017
Journal : EMBO Mol Med
Volume : 9
Pages : 1052-1066

MetaDCN: meta-analysis framework for differential co-expression network detection with an application in breast cancer.

Auteurs : Zhu L, Ding Y, Chen CY, Wang L, Huo Z, Kim S, Sotiriou C, Oesterreich S, Tseng GC
Année : 2017
Journal : Bioinformatics
Volume : 33(8)
Pages : 1121-9

RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial.

Auteurs : Fumagalli D, Venet D, Ignatiadis M, Azim HA Jr, Maetens M, Rothé F, Salgado R, Bradbury I, Pusztai L, Harbeck N, Gomez H, Chang TW, Coccia-Portugal MA, Di Cosimo S, de Azambuja E, de la Peña L, Nuciforo P, Brase JC, Huober J, Baselga J, Piccart-Gebhart M, Loi S, Sotiriou C
Année : 2017
Journal : JAMA Oncol
Volume : 3
Pages : 227-234

Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer.

Auteurs : Buisseret L, Garaud S, de Wind A, Van den Eynden G, Boisson A, Solinas C, Gu-Trantien C, Naveaux C, Lodewyckx JN, Duvillier H, Craciun L, Veys I, Larsimont D, Piccart-Gebhart M, Stagg J, Sotiriou C, Willard-Gallo K
Année : 2016
Journal : Oncoimmunology
Volume : 6
Pages : e1257452

An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers.

Auteurs : Bottai G, Raschioni C, Losurdo A, Di Tommaso L, Tinterri C, Torrisi R, Reis-Filho JS, Roncalli M, Sotiriou C, Santoro A, Mantovani A, Loi S, Santarpia L
Année : 2016
Journal : Breast Cancer Res
Volume : 18
Pages : 121

Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer.

Auteurs : Bense RD, Sotiriou C, Piccart-Gebhart M, Haanen JB, van Vugt MA, de Vries EG, Schröder CP, Fehrmann RS
Année : 2016
Journal : J Natl Cancer Inst
Volume : 109

Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers.

Auteurs : Fumagalli D, Wilson TR, Salgado R, Lu X, Yu J, OBrien C, Walter K, Huw LY, Criscitiello C, Laios I, Jose V, Brown DN, Rothé F, Maetens M, Zardavas D, Savas P, Larsimont D, Piccart-Gebhart M, Michiels S, Lackner MR, Sotiriou C, Loi S
Année : 2016
Journal : Ann Oncol
Volume : 27
Pages : 1860-6

Portraying breast cancers with long noncoding RNAs.

Auteurs : Van Grembergen O, Bizet M, de Bony EJ, Calonne E, Putmans P, Brohée S, Olsen C, Guo M, Bontempi G, Sotiriou C, Defrance M, Fuks F
Année : 2016
Journal : Sci Adv
Volume : 2
Pages : e1600220

Pathway level alterations rather than mutations in single genes predict response to HER2 targeted therapies in the neo-ALTTO trial.

Auteurs : Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Peña L, Loi S, Rosa DD, Chia S, Wardley A, Ueno T, Rossari J, Eidtmann H, Armour A, Piccart-Gebhart M, Rimm DL, Baselga J, Pusztai L
Année : 2016
Journal : Ann Oncol
Volume : 28(1)
Pages : 128-35